基于组效关系的壮药岩黄连抑制HSC-T6细胞增殖活性成分辨识研究

目的建立岩黄连提取物的化学成分与其抑制大鼠肝星状细胞(HSC-T6)作用的组效关系模型,寻找与药效显著相关的活性成分。方法采用正交设计法提取得到9个岩黄连提取物,通过HPLC法对岩黄连提取物进行成分表征,以共有峰的相对峰面积来表征其相对质量分数;MTT法测定岩黄连提取物抑制HSC-T6细胞增殖活性,以抑制率为评价指标;利用SIMCA-P11.5软件的正交投影偏最小二乘法(OPLS)分析,研究共有峰与药效的相关性,根据S-载荷图与变异权重参数(VIP)值辨识显著活性成分;通过MTT法及流式细胞仪验证所筛选成分的活性。采用细胞乳酸脱氢酶(LDH)试剂盒观察所筛选成分对人正常肝细胞(HL-7702)LDH活性的影响。结果 HPLC法对9个岩黄连提取物进行表征分析结果确定了21个共有峰,其中19、18、13、20、14和16号共有峰(VIP1)与岩黄连抑制HSC-T6细胞增殖活性显著相关,并鉴定18、19和20号共有峰代表的化合物分别为脱氢卡维丁、巴马汀和小檗碱。MTT结果显示不同质量浓度脱氢卡维丁、巴马汀及小檗碱对HSC-T6细胞增殖具有明显抑制作用;流式细胞术检测结果也与MTT结果一致,脱氢卡维丁、巴马汀及小檗碱(0.10 mg/m L)处理HSC-T6细胞后的凋亡率分别为42.12%、42.22%、36.73%,明显高于对照组的1.69%(P0.01)。细胞毒性实验发现当脱氢卡维丁终质量浓度低于0.15 mg/m L,巴马汀与小檗碱终质量浓度低于0.10 mg/m L时,对HL-7702细胞不具有明显的细胞毒作用。结论通过组效关系研究首次发现岩黄连提取物中脱氢卡维丁、巴马汀与小檗碱在体外能显著抑制HSC-T6细胞增殖并诱导其凋亡,且在有效质量浓度下不具有明显的细胞毒作用,表明这3种化学成分极有可能是岩黄连抗肝纤维化作用的潜在活性成分且在应用中具备一定的安全性;同时也提示基于组效关系的研究思路可为天然植物药活性成分的辨识提供行之有效的方法。     

Box-Behnken设计-效应面法优化岩黄连碱纳米结构脂质载体处方工艺及体外药效评价

目的 Box-Behnken设计-效应面法优化岩黄连碱纳米结构脂质载体(dehydrocavidine nanostructured lipid carriers,DC-NLCs)处方,并进行体外药效研究。方法 采用溶剂蒸发法制备DC-NLCs。以包封率、载药量和ζ电位为考察指标,采用单因素考察和Box-Behnken设计-效应面法优化DC-NLCs的处方。对DC-NLCs进行表征,并考察体外药效作用。结果 最佳处方为投药量为10.0mg、固-液脂质比为1:8、卵磷脂用量为85.0mg、表面活性剂为1%聚山梨酯-80。DC-NLCs测得包封率为(85.29±0.01)%,载药量为(6.27±0.00)%,ζ电位为(-17.90±1.09)mV、粒径为(188.50±11.77)nm,体外释药具有明显的缓释特征。体外药效学实验表明,DC-NLCs体外抑制肝纤维化的效果显著。结论 Box-Behnken设计-效应面法所建立的模型能较好地用于DC-NLCs处方优化,准确度高,预测效果较好,且优化制备的DC-NLCs具有显著的抑制肝纤维化作用。     

HPLC法测定岩黄连中不同部位脱氢卡维丁的含量

目的：建立岩黄连中不同部位脱氢卡维丁的高效液相色谱定量测定方法。方法：采用ZorbaxODS C18（250mm×4．6mm,5μm）色谱柱,以乙腈-0．05mol／L磷酸二氢钾溶液（用10%GKOH调pH至5．0）（85：15）为流动相,流速1．0mL／min,检测波长为347nm,柱温为室温。结果：脱氢卡维丁在2．51～75．36μg／mL（r=0．99999,n=7）范围内线性关系良好,平均回收率为99．86％,RSD为0．58％。结论：该法简单、快速、重现性好,适用于岩黄连中脱氢卡维丁的定量分析。     

反相高效液相色谱法测定岩黄连药材中脱氢卡维汀的含量

目的:建立反相高效液相色谱法测定岩黄连药材中脱氢卡维汀的含量,并用该方法测定不同采收时间、不同部位岩黄连药材中脱氢卡维汀的含量。方法:采用 Phenomenex Gemini-C_(18)色谱柱(250 mm×4.6 mm,5 μm);流动相为乙腈-0.02mol·L~(-1)磷酸二氢钾溶液(74:26),二元等度洗脱系统;流速为1.0 mL·min~(-1);检测波长346 nm;柱温为室温。结果:脱氢卡维汀浓度在8.4～84μg·mL~(-1)范围内线性良好,回归方程为 Y=8.550×10~4X-1019(r=0.9998),低、中、高3个加入量的平均回收率分别为101.3%,102.0%,105.3%;RSD 分别为2.8%,2.3%,2.4%;不同采收时间岩黄连全草中脱氢卡维汀的含量为1.72%～2.07%,在根、茎、叶、花中的含量分布为花>根>叶>茎。结论:本方法简便、准确,重复性好,适用于岩黄连药材的质量控制研究。     

岩黄连总碱胶囊在健康受试者体内的药动学研究

目的:建立LC-MS/MS法测定人血浆中脱氢卡维丁的浓度,研究不同剂量岩黄连总碱胶囊在中国健康受试者多次给药后的药动学.方法:采用随机、开放、多剂量给药设计的方法.16名健康志愿者随机分为2个剂量组(2 400 mg和3 200 mg),男女各半,每组8例,分别多次口服岩黄连总碱胶囊,每日1次,连续7 d,第7天在给药...     

HPLC测定岩黄连注射液中岩黄连碱的含量

目的:建立 HPLC 法岩黄连注射液中岩黄连碱的含量。方法:Luna C_(18)色谱柱(250 mm×4.6 mm,5μm),流动相为乙腈-水(1:1,1000 mL 含磷酸二氢钾3.4 g,十二烷基硫酸钠1.7g),流速1.0 mL·min~(-1),检测波长347 nm,柱温为室温。结果:岩黄连碱在5.48～49.34μg·mL~(-1)浓度范围内呈良好的线性关系(r=1.0000);方法平均加样回收率为99.96%,RSD=0.41%(n=6)。结论:本法可作为岩黄连注射液的质量控制方法。     

Evaluation of genotoxicity of Yanhuanglian dehydrocavidine (YHL-DC) in vitro and in vivo

It is reported that dehydrocavidine (DC), the main component of a traditional Chinese medicine, Yanhuanglian (YHL), can protect hepatic tissue against HBV and HAV impairment. As part of a safety evaluation on YHL-DC for use in the treatment of HBV, the present study evaluated the potential genotoxicity of YHL-DC by using the standard battery of tests (i.e., bacterial reverse mutation, chromosomal aberrations, and mouse micronucleus assays) recommended by the State Food and Drug Administration of China. The results showed that YHL-DC was not genotoxic under the conditions of the reverse mutation, chromosomal aberrations, and mouse micronucleus assay conditions. The anticipated clinical dose should be smaller than the doses used in the genotoxicity assays. With confirmation from further toxicity studies, YHL-DC would hopefully prove to be a useful anti-HBV agent.     

Protective effects of dehydrocavidine on carbon tetrachloride-induced acute hepatotoxicity in rats

AIM OF THE STUDY: To investigate the protective effects of dehydrocavidine (DC), a main active ingredient of Corydalis saxicola Bunting (Yanhuanglian), on carbon tetrachloride (CCl4)-induced hepatotoxicity and the possible mechanisms involved in male Sprague-Dawley rats. MATERIALS AND METHODS: Acute hepatotoxicity was induced by CCl4 intoxication in rats. Serum biological analysis, lipid peroxides and antioxidants estimation, histopathological studies were carried out. RESULTS: Both pre-treatment with DC prior to CCl4 administration and post-treatment with DC after CCl4 administration significantly prevented increases in serum enzymatic activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), alkaline phosphatase (ALP) and total bilirubin (TBIL). In addition, pre- and post-treatment with DC also significantly prevented formation of hepatic malondialdehyde (MDA), depletion of glutathione peroxidase (GPx) and depression of superoxide dismutase (SOD) in the liver of CCl4-intoxicated rats. ALT, AST, LDH, ALP and TBILL levels, as well as MDA, SOD and GPx activities were unaffected in normal rats by treatment with DC alone. GST, a phase II enzyme, had no significant changes during our experiments. Histopathological changes induced by CCl4 were also significantly attenuated by DC treatment in both preventive and curative experiments. CONCLUSIONS: DC has a potent hepatoprotective effect on CCl4-induced liver injury in rats through its antioxidant activity.